Message from Melvin L. Mayer, MD, Program Chair of the 2011 Annual Meeting

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.